Rockwell Automation vs Revvity Inc — how do they compare? Rockwell Automation trades at $451.91 (market cap $49.64B), while Revvity Inc trades at $116.34 (market cap $12.91B). The key difference: Rockwell Automation is far larger — about 3.8× Revvity Inc's market cap, and Rockwell Automation pays the higher dividend (1.23%). Which is the better fit depends on your goals.
| ROK | RVTY | |
|---|---|---|
Market Cap | $49.64B | $12.91B |
Sector | Industrials | Technology |
52-Week High | $495.08 | $117.75 |
52-Week Low | $333.75 | $82.26 |
Enterprise Value | $52.77B | $15.23B |
Dividend Yield | 1.23% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $450.36, up 3.48% today, with a neutral technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $3.49, exceeding expectations, and raised full-year guidance amid robust demand in automation markets. Valuation ratios are elevated with a P/E of 41.85, but profitability remains solid with a net income margin of 13.38%.
Outlook is positive due to consistent earnings outperformance and AI-driven growth initiatives, though high valuation and inflationary cost pressures present risks. The consensus price target of $507.00 implies potential upside, supported by a majority analyst hold rating reflecting cautious optimism.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Trailing returns across standard periods
Latest headlines on both assets
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →